Caisse DE Depot ET Placement DU Quebec Has $90.43 Million Stock Position in Stryker Co. (NYSE:SYK)

Caisse DE Depot ET Placement DU Quebec lessened its holdings in Stryker Co. (NYSE:SYK) by 1.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 251,160 shares of the medical technology company’s stock after selling 4,276 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned approximately 0.07% of Stryker worth $90,430,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. J. W. Coons Advisors LLC grew its holdings in Stryker by 0.7% during the 4th quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock worth $1,315,000 after acquiring an additional 26 shares during the period. Mascoma Wealth Management LLC grew its stake in shares of Stryker by 22.7% during the fourth quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company’s stock worth $53,000 after purchasing an additional 27 shares during the period. Opal Wealth Advisors LLC increased its holdings in Stryker by 1.6% in the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock valued at $654,000 after purchasing an additional 28 shares during the last quarter. Lindbrook Capital LLC lifted its stake in Stryker by 2.0% in the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company’s stock valued at $507,000 after buying an additional 28 shares during the period. Finally, Alhambra Investment Management LLC boosted its holdings in Stryker by 1.5% during the fourth quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock worth $719,000 after buying an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on SYK shares. Royal Bank of Canada increased their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 target price on shares of Stryker in a report on Friday, March 21st. BTIG Research set a $403.00 price target on shares of Stryker and gave the company a “buy” rating in a report on Monday, April 14th. Stifel Nicolaus raised their price objective on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Finally, Barclays boosted their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $424.56.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.90% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $374.57 on Friday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company’s fifty day simple moving average is $366.62 and its 200-day simple moving average is $373.60. The firm has a market cap of $142.97 billion, a PE ratio of 48.27, a P/E/G ratio of 2.93 and a beta of 0.93. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping the consensus estimate of $2.73 by $0.11. The firm had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The company’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the firm posted $2.50 EPS. Equities research analysts expect that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were paid a $0.84 dividend. The ex-dividend date was Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.90%. Stryker’s dividend payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.